Our Roadmap
Join us on a mission to transform early disease detection. The TOBY™ platform is built to detect multiple conditions early, using a single, simple urine sample. While our long-term vision is to expand across various disease conditions, we recognize that groundbreaking change starts with focused, decisive steps.
Explore our development journey and see how we’re shaping the future of early detection.
Published Research
TOBY’s multicenter study evaluated urinary VOCs and AI for multi-cancer detection across 10 cancer types.
Early detection starts with urine.
10 Cancers. One Test.
Breast Cancer
Cancer Cases: 12.5%
Lung Cancer
Cancer Cases: 12.2%
Colorectal Cancer
Cancer Cases: 10.7%
Prostate Cancer
Cancer Cases: 7.8%
Stomach Cancer
Cancer Cases: 6.0%
Bladder Cancer
Cancer Cases: 3.2%
Pancreatic Cancer
Cancer Cases: 2.7%
Cervical Cancer
Cancer Cases: 2.7%
Kidney Cancer
Cancer Cases: 2.4%
Ovarian Cancer
Cancer Cases: 1.7%
Be part of the movement for early detection via mass spectrometry of urine and artificial intelligence
Read TOBY’s new publication in Cancer Reports.
